105 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
been received and accepted. If you have not been provided with your meeting access credentials, please ensure you contact Computershare on the morning … of the AGM, but no later than 2 hours before the start of the AGM.
Access to the AGM via meetnow.global/IHCAGM2024 will be available from 2.15 p.m
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
of the registration statement through the SEC’s website, as provided above.
We also maintain a website at www.immunocore.com through which you can access our … for cash all of the Gates Foundation’s shares pursuant to our amended global access commitments agreement with the Gates Foundation.
On May 12, 2022
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
appointment having been received and accepted. If you have not been provided with your meeting access credentials, please ensure you contact … Computershare on the morning of the AGM, but no later than 2 hours before the start of the AGM.
Access to the AGM via meetnow.global/IHCAGM2024 will be available
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
for cash all of the Gates Foundation’s shares pursuant to our amended global access commitments agreement with the Gates Foundation.
On May 12, 2022 … and other information with the SEC. Our SEC filings are available to the public at the SEC’s website at www.sec.gov. You also may access these filings
8-K
EX-99.1
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increasing commercial access to KIMMTRAK globally, and pursuing future growth … access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor
8-K
EX-99.2
stydeo5zhbd4xgv
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
7528ft
28 Feb 24
Annual report
7:33am
10-K
EX-10.12
ztzzdkv f20d
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
kk5fvwj2xzf0ba
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
byup83hdxrtjspmrao1d
28 Feb 24
Annual report
7:33am
8-K
EX-99.2
4a0cqpdf
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
8-K
EX-99.2
r3j7vhp
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
8-K
EX-99.1
y0jbsx0
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.2
pip14iu2gbpknhg6g k8
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
5xsy3z
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
u4tqmax7
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
rflx t2f9wbo1iyiv5n
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
2x3rfoz6t
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
2rs12ap3zov92viu8
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
ixap6dnmv90
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am